Table 2.
Secondary Outcomes
| Outcome | Magnesium Group | Placebo Group | P |
|---|---|---|---|
| Total patients | n = 77 | n = 81 | |
| With/without history of eczema and/or family history of asthma | n = 38/39 | n = 40/41 | |
| Patients needing clinic visits but not infirmary in 2 wk after discharge | 26 (33.8) | 22 (27.2) | .36 |
| Eczema and/or family history of asthma | 17 (44.7) | 14 (35) | .38 |
| No history of eczema and/or family history of asthma | 9 (23.1) | 8 (19.5) | .69 |
| Patients needing infirmary care but not hospital admission in the 2 wk after discharge | 11 (14.2) | 4 (4.9) | .05 |
| Eczema and/or family history of asthma | 8/38 (21.0) | 3/40 (7.5) | .19 |
| No history of eczema and/or family history of asthma | 3/39 (7.6) | 1/41 (2.4) | .35 |
| Patients needing hospital admission in the 2 wk after discharge | 4 (5.2) | 1 (1.2) | .20 |
| Eczema and/or family history of asthma | 2 (5.3) | 0 (0.0) | .23 |
| No history of eczema and/or family history of asthma | 2 (5.1) | 1 (2.4) | .61 |
Data are presented as No. (%) unless otherwise indicated.